|
Oct 3
|
Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
|
|
Oct 3
|
2 Passive Income Stocks to Load Up On in October
|
|
Oct 2
|
STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
|
|
Oct 1
|
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
|
|
Oct 1
|
A schizophrenia win for BMS’ Cobenfy, but challenges lie ahead
|
|
Oct 1
|
BMS and Prime ink potential $3.5bn deal to develop T cell therapies
|
|
Oct 1
|
Read This Before Considering Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming US$0.60 Dividend
|
|
Oct 1
|
5 FDA decisions to watch in the fourth quarter
|
|
Oct 1
|
Bristol-Myers Squibb Company (BMY) is Driving Growth Through Strategic Acquisitions
|
|
Sep 30
|
Sector Update: Health Care Stocks Advance Late Afternoon
|
|
Sep 30
|
US Judge Dismisses $6.4 Billion Suit Against Bristol Myers Over Delay in Drug Approvals
|
|
Sep 30
|
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
|
|
Sep 30
|
Company News for Sep 30, 2024
|
|
Sep 30
|
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
|
|
Sep 30
|
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
|
|
Sep 30
|
Prime to narrow gene editing research as it strikes deal with Bristol Myers
|
|
Sep 28
|
3 Surprisingly Underrated Stocks to Buy Right Now
|
|
Sep 27
|
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
|
|
Sep 27
|
These Stocks Moved the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More
|
|
Sep 27
|
Dow Rises to Record; Chinese Indexes Post Best Week in Years
|